Sign In
Buy GOSS
$0.188
-0.0119 (-5.94%)
At Close: Jun 03, 2026
SAN FRANCISCO, May 08, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchase
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:59am, Friday, 08'th May 2026
LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:59am, Friday, 08'th May 2026
LOS ANGELES, May 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer�
GOSS UPCOMING DEADLINE : The Gross Law Firm Alerts Gossamer Bio, Inc. Stockholders of Securities Class Action - Contact the Firm
09:00am, Friday, 08'th May 2026
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the cla
New York, New York--(Newsfile Corp. - May 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and Febru
DEADLINE ALERT for GOSS, NUAI, and MEDP: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12:08pm, Thursday, 07'th May 2026
LOS ANGELES, May 07, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded c
Bronstein, Gewirtz & Grossman LLC Urges Gossamer Bio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 07'th May 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer B
Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop on Phase 3 PROSERA Trial Failure - Hagens Berman
11:49am, Thursday, 07'th May 2026
San Francisco, California--(Newsfile Corp. - May 7, 2026) - A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors
GOSS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
11:44am, Thursday, 07'th May 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options If you purchased or acquire
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors
Important Information Regarding Section 20(a) Individual Liability Claims NEW YORK, May 7, 2026 /PRNewswire/ -- SueWallSt alerts investors in Gossamer Bio, Inc. (NASDAQ: GOSS) of a pending securities
New York, New York--(Newsfile Corp. - May 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 202
LOS ANGELES, May 06, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the class action filed on beh
Key Dates and Disclosure Events Shareholders Need to Know NEW YORK, May 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Gossamer Bio, Inc. (NASDAQ: GOSS) to c
